ExodusPoint Capital Management’s Starling Oncology STLN Stock Holding History
Bought
Maintained
Sold
Other funds holding STLN
JAIC
ExodusPoint Capital Management's STLN Position: Q3 2026 in Review
ExodusPoint Capital Management sold out of Starling Oncology (STLN) in Q3 2026, closing a stake of 33,644 shares — an estimated $183K sold.
ExodusPoint Capital Management first reported a position in STLN in Q4 2021 and held it in 6 quarters. The position peaked at $759K in Q1 2022. 130 funds tracked by Wall St. Rank hold STLN as of Q3 2026.
- ExodusPoint Capital Management reported no remaining Starling Oncology position as of Q3 2026 after selling out during the quarter.
- ExodusPoint Capital Management sold 33,644 Starling Oncology shares in Q3 2026, an estimated $183K.
- ExodusPoint Capital Management first reported a position in Starling Oncology in Q4 2021 and held it in 6 quarters.
- ExodusPoint Capital Management's Starling Oncology position peaked at $759K in Q1 2022.
- 130 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.
Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.